Pharmabiz

Pharming’s Joenja receives European marketing authorization for the treatment of activated PI3K delta syndrome

Pharming’s Joenja receives European marketing authorization for the treatment of activated PI3K delta syndrome: Leiden, the Netherlands Tuesday, May 26, 2026, 13:00 Hrs [IST] Ph ...

European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union

Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a ...
pharmaphorum

First drug for rare disease APDS cleared for NHS use

Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), an ultra-rare immunodeficiency ...
Monthly Prescribing Reference

Leniolisib Gets Priority Review for Young Children With APDS

A Prescription Drug User Fee Act target date of January 31, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug ...
PharmaTimes

Pharming’s APDS drug scores EU orphan status

Pharming’s investigational treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) has been granted orphan drug designation from the European Commission. The designation awarded to ...
Smart Business Magazine

APDS hones its services to meet community needs

While the Africentric Personal Development Shop may not be well known by the Greater Columbus community, CEO Jerry Saunders Sr. says it has the most important factor down — street credibility. Since ...
The Independent

Breakthrough for teen who lost four family members to inherited condition

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...